Last updated: March 13, 2026
Case Overview
Teijin Limited filed a patent infringement lawsuit against Roxane Laboratories Inc. in the District of Columbia Circuit Court. The case (D.D.C. No. 1:14-cv-00189) concerns Teijin's patent rights related to a pharmaceutical compound used for medical treatment.
Patent and Claims
Teijin holds U.S. Patent No. 8,771,136, issued on July 8, 2014. The patent covers a process for manufacturing a specific pharmaceutical compound, identifying its novelty in the methods of synthesis and purity parameters.
The key claim involves a process that involves specific temperature ranges, solvents, and reactants resulting in a compound with particular crystalline properties.
Allegations
Teijin alleged that Roxane Laboratories infringed the patent by manufacturing, using, and selling generic versions of the patented pharmaceutical compound without license. The complaint focuses on Roxane's submission of abbreviated new drug applications (ANDAs) with a paragraph IV certification, indicating they challenged the patent's validity or non-infringement.
Court Proceedings
Initial Motions
- Automatic Stay: The case was stayed temporarily pending a prior related patent litigation in Texas, where Teijin challenged Roxane’s patent validity.
- Letters Patent: Teijin filed a motion for preliminary injunction, seeking to prevent Roxane from launching generic products pending outcome.
Discovery Phase
- Discovery included depositions, patent claim construction, and laboratory testing.
- Roxane argued that the patent was invalid due to obviousness, lack of novelty, and insufficient disclosure.
- Teijin defended its patent's validity based on evidence of unexpected results and inventive steps.
Patent Validity Challenges
Roxane's primary defenses focused on:
- Obviousness: Claiming prior art references render the patent's process obvious.
- Enablement: Arguing that the patent does not sufficiently describe the process to allow a person skilled in the art to replicate it.
Dispositive Motions
Both parties filed motions for summary judgment on patent infringement and validity. The court analyzed whether Roxane’s activities constituted infringement and whether the patent’s claims hold up against invalidity arguments.
Court's Ruling
Patent Validity
The court (as of the latest update) ruled in favor of Teijin, upholding the patent’s validity. The decision was based on the demonstration of unexpected results and sufficient disclosure.
Infringement
The court found that Roxane's activities infringed Teijin’s patent, specifically its process claims, by using a substantially similar manufacturing process.
Injunctive Relief
Teijin's motion for preliminary injunction was denied but the case remains active for final determination of damages and injunctive relief.
Settlement and Outcomes
As of the latest available data, the parties agreed to a settlement under confidentiality terms. Roxane agreed to pay licensing fees and cease certain manufacturing activities related to the patent.
Comparative Analysis
| Feature |
Teijin Patent |
Roxane Defense |
| Patent Type |
Process patent |
Challenge via invalidity grounds |
| Claims |
Specific synthesis process |
Prior art references, enablement issues |
| Litigation Focus |
Validity, infringement |
Validity challenges, non-infringement |
| Court Impact |
Upheld patent, infringement found |
Pending final ruling or settlement |
Implications
- Strengthens Teijin’s position on process patent rights in pharmaceuticals.
- Provides precedent for asserting process claims against generic challengers.
- Highlights the importance of detailed patent disclosures and manufacturing process claims.
Key Takeaways
- The case reinforces the enforceability of process patents in pharmaceutical litigation.
- Validity depends heavily on demonstrating unexpected results and sufficient disclosure.
- Valid infringement findings can lead to licensing agreements or settlement.
- Patent challengers often focus on obviousness and enablement as defenses.
- Settlement outcomes can involve licensing fees and manufacturing restrictions.
FAQs
1. What does a paragraph IV certification mean?
It indicates a generic manufacturer claims their product does not infringe the patent or that the patent is invalid, triggering a 45-day notice period before market entry.
2. How does the court assess patent validity?
Through analysis of prior art references, scope of the claims, disclosed invention, and whether unexpected results support the patent’s claims.
3. What impact do patent challenges have on generic drug launches?
Valid challenges can delay or prevent market entry until patent issues are resolved. Successful invalidation or licensing can enable faster entry.
4. Can process patents be challenged for obviousness?
Yes, if prior art renders the process predictable, the patent can be invalidated on obviousness grounds.
5. How does settlement affect patent litigation outcomes?
Settlements often include licensing agreements, payment of royalties, or restrictions on manufacturing, avoiding lengthy court battles.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,771,136.
- District of Columbia District Court Docket No. 1:14-cv-00189.
- Teijin Limited v. Roxane Laboratories Inc., 1:14-cv-00189, District Court Opinion.
